Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis

被引:22
作者
Costenbader, Karen H. [1 ]
Glass, Roberta [1 ]
Cui, Jing [1 ]
Shadick, Nancy [1 ]
机构
[1] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 18期
关键词
D O I
10.1001/jama.296.18.2201-a
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
引用
收藏
页码:2201 / 2201
页数:1
相关论文
共 2 条
[1]
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285
[2]
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37